Immunpluimnometric assays for lactoferrin and elastase-cti-proteinase inhibitor complexes were developed using solid-phase methodology, which has already been published from this laboratory. The aim of the study was to develop ä rapid method to see whether elevated granulocyte activity was present in the lung, as for example in neonatal sepsis. The lactoferrin assay gave reliable results within 30 minutes, the elastase^ttt-proteinase inhibitor complexes, within 5 hours.
Introduction
It is often difficult to determine causes of lung dysfunction and sepsis in neonates. The aim of this study was to combine the sensitivity of luminescent detection systems and the specificity of leukocyte analytes (in this case, elastase and lactoferrin) for use in a paediatric clinic and intensive care unit.
We describe the development and clinical evaluation of immunoluminometric assays for lactoferrin and elastase-ttj-proteinase inhibitor complexes in plasma and bronchoalveolar lavage samples.
Both analytes monitor granulocyte activity (1) (2) (3) , and are useful in monitoring inflammatory disease with possible bacterial involvement, where other analytes, for example C-reactive protein alone, provide insufficient data. In this article special mention is made of lung diseases, especially pneumonia and neonatal sepsis. Since the assay is very sensitive, requiring a sample volume of less than 50 μΐ for the determination of both components, both tests are suitable for perinatal diagnosis and monitoring.
The elastase is present in the primary vesicles of polymorphonuclear leukocytes (4) and is set free during normal or "frustrated" phagocytosis or cell destruction. Lactoferrin is not only present in polymorphonuclear leukocytes (5) , but is also present in pancreatic juice (6) , milk (7) and synovial fluid (5) , so that the determination in plasma is not as specific as that of elastase-drproteinase inhibitor complexes. Theoretically all body fluids are suitable for the determination of elastase complexes and lactoferrin, dependent upon the site of inflammation. Bronchoalveolar lavage may form the ideal sample if granulocyte activity is to be monitored in respiratory disease.
EDTA plasma was the material of choice for blood concentration measurements (8) . Although in practice citrate and oxalate plasma could be used, the dilution factor (1 part citrate/oxalate -f-9 parts blood) must be taken into consideration. A commercial enzyme immunoassay (PMN-Elastase ELISA, Merck, Darmstadt, D), which requires regular routine experience to obtain optimal results, is available for measuring elastase-ai-proteinase inhibitor complexes. The results for the Merck test are available about 6 hours after taking the sample.
A solid-phase radioimmunoassay for lactoferrin has been published by Bennett & Mohle (9) , in which serum concentrations were higher than plasma concentrations, and in which the "leak" process was followed in serum, heparin and EDTA plasma over several hours.
The assays developed and validated in the present work are suitably robust and reproducible for routine use, and do not involve the use of a radioactive label.
Materials and Methods
Immunoluminometric assays using polystyrene balls as solidphase have been published previously from this laboratory (10) (11) (12) (13) (14) .
Antisera
Antiserum to ctj-proteinase inhibitor was purchased from Cappel Laboratories (Organon Teknika N.V., Turahout, B). Antiserum to human elastase was obtained from Serotec (Camon GmbH, Wiesbaden, D).
The two antisera for the lactoferrin assay were obtained from Cappel and Dakopatts (Hamburg, D) respectively. Polystyrene balls (6.4 mm diameter) were bought from Spherot ech Kugeln (Fulda, D).
Antibodies were labelled with N-(7-(4-aminobutyl-N-ethyl) naphthalene-l,2-dicarboxylic acid hydrazide) hemisuccinamide (ABEN-H) as previously published (10) .
Standards
Lactoferrin and a\-antitrypsin (arproteinase inhibitor) were obtained from Sigma, Deisenhofen, D, elastase from Protogeh, L ufelfingen, CH. The elastase standard was complexed with an excess of purified cti-proteinase inhibitor in a molar ratio of 1:35 (i.e. under physiological conditions). Complex formation was monitored by loss of elastase activity, determined photometrically with the synthetic substrate Me-O-Suc-(Ala) 2 -Pro-Val-nitroanilide (Bachern, Bubendorf, CH). The nominal values of the elastasectj-proteinase inhibitor are given in terms of the elastase content.
Lactoferrin standards were made up in foetal calf serum as this was shown to be free of immunoreactive lactoferrin.
Samples
EDTA blood samples were obtained from patients with and without lung infections, as well as from healthy blood donors with normal blood sedimentation rate, normal blood smear, aminotransferases and γ-glutamyl transferase. The blood samples were left to stand for 30 minutes at 4°C before being centrifuged at 2000 £ for 10 min. Ttie' supernatant was then removed, portioned and stored at -20 °C until assayed. Full EDTA blood samples older than 2 hours could not be used as the "leak process" had already started, giving rise to falsely elevated results. Bronchoalveolar lavage was obtained from different patient groups, using a published standardised method (15) .
Tables la and Ib show the assay schemes for the elastase-a r proteinase inhibitor complex assay (PMN-Elastase) from Merck, (Darmstadt, D) and the immunoluminometric assay developed in this laboratory. Horizontal rotators (Heidolph Horizontalrotierer, Abbott, Wiesbaden, D) were used for the incubation steps. The washing procedures were performed using an automatic washing system (Pentawash or Pro-quantum, Abbott, Wiesbaden, D). Table 2 shows the imprecision using compound precision profiles and inter-assay imprecision for both assays. Figure 1 shows typical standard curves for elastasect!-proteinase inhibitor and lactoferrin assays, respectively.
Results
The effect of 5 different dilution media for the elastase-cti-proteinase inhibitor assay was tested, the results being shown in table 3.
Recovery experiments were carried out on two plasma samples with low and high concentrations, the results being listed in table 4. The elastase-at-proteinase inhibitor recovery was determined additively, the lac-.toferrin recovery by using an admixture of 2 samples. In addition the mean recovery of elastase from the addition of two plasma samples was measured in 8 consecutive assays: Plasma 1-98 μg/l, Plasma 2 -347 μg/l. Expected value -445 μg/l, mean value found -472 μ §/1, mean recovery 106%. The mean lower detection limit of the elastase-diproteinase inhibitor complex assay, measured as μg/l elastase was 0.3 μ §/1 (12 fg/tube) (or in the plasma assay 15 μ §/1 -allowing for the 50-fold sample dilution).
This represented the mean + 3 s value of the zero standard read from 20 standard curves. This value did not overlap the -3s value of the first standard point. For lactoferrin in a similar study, the mean lowest detection limit was 0.04 mg/1 (0.4 pg/tube) using a 10 μΐ plasma sample.
Lipaemic and icteric sera did not interfere in the assay, probably due, amongst other things, to the small sample volume (less than 4% of the total incubation volume).
Haemolysed samples were discarded unless intravascular haemolysis was expected or was not to be excluded (e.g. Rh-erythroblastosis). These findings comply with those of Neumeier et al. (17) . Purified haemoglobin did not affect the results of other assays when added to the plasma sample to be measured at a concentration of 1 g/1.
The specificity of the elastase assay was tested with pure human α,-proteinase inhibitor (Sigma) complexed with human pancreatic elastase and porcine pancreatic elastase. Neither preparation reacted in the assay even at concentrations of 20 mg/1 elastase complexes.
Tab The lactoferrin assay was specific for lactoferrin and did not cross-react with transferrin, even when the latter was present at a concentration of 10 g/1.
In the lactoferrin assay, the same results were obtained after 30, 60 and 90 minutes incubation times (y = a + bx) n = 25 different plasma samples in each case. For 30 min v 60 min r = 0.988; ayx ~ 0.002; byx = 0.981. This validation data was needed to reduce the time between taking the sample and receiving the results. Table 5a shows the reference range established for elastase-arproteinase inhibitor complexes in EDTA plasma from healthy blood donors and the concentrations of this analyte in dialysis patient plasma. Table 5b shows the same for lactoferrin values in EDTA plasma and in serum taken after the blood had been allowed to clot for at least 30 minutes. The difference between plasma and serum was statistically significant for lactoferrin (Mann-Whitney U-test: z = 3.94, p < 0.01).
The difference before and after dialysis was statistically significant for both elastase and lactoferrin (Wilcoxon signed rank test: c a elastase = 6.23, c a lactoferrin = 5.90, p < 0.01 in both cases). Figure 2 shows the correlation of elastase (measured in complex with added a r proteinase inhibitor) and lactoferrin in the supernate of a leukocyte preparation after serial dilution, centrifugation, and two freezethaw cycles. Before freezing and thawing, the supernate contained no measurable elastase or lactoferrin. Figure 3 shows the values for elastase a t -proteinase inhibitor and lactoferrin in bronchoalveolar lavage in selected patients with chronic obstructive lung disease and bacterial pneumonia. The median concentration of elastase was 223 μg/l (range 230 -1320) and of lactoferrin 0.20 mg/1 (range < 0.05-3.05 mg/1). Figure 4 shows the correlation between the commercial enzyme immunoassay and the luminescent immunoassay in plasma from healthy and diseased patients.
Discussion
Lactoferrin can be determined rapidly and usually correlates with elastase concentrations, when the latter is determined in a complex with arproteinase inhibitor (see tab. 5 and fig. 2 ). The lactoferrin results can be returned to the ward within one hour, which is important in the treatment of neonatal sepsis cases. Patient no. It has been shown that lactoferrin is present in other body fluids and organs such as milk (7) and pancreas juice (6) , so that plasma concentrations do not originate entirely from granulocyte destruction as in the case of granulocyte elastase. Although pancreatic elastase is also released in small amounts into the bloodstream, it does not react in this assay.
Both assays are simple to perform and are specific, sensitive and reproducible enough for determinations in plasma or lung lavage. The elastase ILMA is simpler to carry out than the elastase ELISA (see tab. la and Ib) because of the fewer wash and incubation steps.
The determination in bronchoalveolar lavage is theoretically more specific for lung sepsis cases because additional sources of elastase and lactoferrin are excluded, and because the concentrations are measured at the "site of action". Attempts at standardising the lactoferrin and elastase complex*concentrations by relating them to albumin or urea in the bronchoal-veolar lavage were abandoned as no improvement in separation between non-sepsis and sepsis groups was seen. This is in agreement with other findings (13, 15) for proteins in lavage.
The choice of assay buffer for the elastase-a r proteinase inhibitor ILMA was relatively unimportant, provided that ovalbumin was not added; addition of ovalbumin gave rise to higher results (tab. 3 column 2).
Leukocyte destruction during haemodialysis can be monitored using these assays (18, 19) . Studies were performed before and after haemodialysis, to test the assays for expected increases in lactoferrin and elastase complexes (see tab. 5). The relationship of elastase-cii-proteinase inhibitor complexes to lactoferrin was studied in these patients, as the literature mainly deals with elastase. The studies were performed as a prerun for testing leukocyte destruction using different haemodialysis membranes.
Unfortunately, commercial kits for elastase-arproteinase inhibitor complexes are at present expensive and time consuming (see tab. la) although the producer has announced that a "rapid-version" of the assay will soon be available. The assay developed here correlated well with the commercial assay on plasma samples from infants, as figure 3 shows.
In measuring these two analytes, we monitor a paradox, inasmuch as the elastase released is capable of digesting lung tissue, when not complexed with ajproteinase inhibitor. On the other hand, lactoferrin has a bacteriostatic action (18 -19) and promotes polymorphonuclear leukocyte adhesiveness (21) .
The possibility cannot be excluded that lactoferrin also plays a role in removing active oxygen species such as free radicals and Superoxide ions. It has been found that transferrin and ferritin are also elevated in bronchoalveolar lavage from such patients (23) . All three proteins contain trivalent iron, which can be reduced to bivalent iron by active oxygen anions and radicals. In conclusion, assays are described for two components of polymorphonuclear leukocytes. Although the aim was to set up assays for monitoring cases of neonatal sepsis, it is possible to answer other questions regarding leukocyte activity and destruction by measuring these two compounds. Especially important is the fact that these assays provide reliable results of leukocyte involvement within an hour of receiving samples, which is crucial in neonatal intensive care.
